Curis reported a net loss of $10.6 million for the first quarter of 2025, an improvement from the $11.9 million net loss in the same period of 2024. Revenues increased to $2.4 million from $2.1 million year-over-year, primarily driven by royalty revenues from Erivedge® sales. The company also announced the appointment of Dr. Ahmed Hamdy as Chief Medical Officer and made progress with regulatory discussions for emavusertib.

Curis, Inc. reported a net loss of $9.6 million for the fourth quarter of 2024, an improvement from a net loss of $11.7 million in the same period last year. Revenues for the quarter were $3.3 million, up from $2.7 million in Q4 2023. The company also announced positive clinical data for emavusertib in TakeAim Lymphoma and Leukemia studies, and secured Orphan Drug Designation for PCNSL in both the US and EU.

Curis reported a net loss of $10.1 million, or $1.70 per share, for the third quarter of 2024, compared to a net loss of $12.2 million, or $2.13 per share, for the same period in 2023. Revenues for the third quarter of 2024 were $2.9 million, compared to $2.8 million for the same period in 2023. The company's cash and cash equivalents totaled $31.6 million, including the impact of the October 2024 Offerings, and expects its existing cash and cash equivalents will enable its planned operations into mid-2025.

Curis reported a net loss of $11.8 million, or $2.03 per share, for the second quarter of 2024, compared to a net loss of $12.0 million, or $2.47 per share, for the same period in 2023. Revenues for the second quarter of 2024 were $2.5 million, compared to $2.2 million for the same period in 2023. The company's cash, cash equivalents, and investments totaled $28.4 million as of June 30, 2024, and expects its existing resources will enable planned operations into the first quarter of 2025.

Curis reported a net loss of $11.9 million, or $2.05 per share, for the first quarter of 2024. Revenues were $2.1 million, consisting of royalty revenues from Genentech/Roche's sales of Erivedge®. The company's cash, cash equivalents, and investments totaled $40.7 million as of March 31, 2024, and expects its existing resources will enable planned operations into 2025.

Curis, Inc. reported its Q4 2023 financial results, featuring a net loss of $11.7 million, and provided a business update highlighting emavusertib data presented at ASH and expansion of clinical sites in the US and Europe. They expect their cash to last into 2025.

Curis, Inc. reported a net loss of $12.2 million for Q3 2023, with revenues of $2.8 million from royalties. The company is advancing its clinical development of emavusertib, with ongoing trials and upcoming data presentations.

Curis reported a net loss of $12.0 million, or $0.12 per share, for the second quarter of 2023. The company's cash, cash equivalents, and investments totaled $77.4 million, expected to fund operations into 2025. The partial clinical hold on the TakeAim Leukemia study was removed, and the RP2D for emavusertib monotherapy was confirmed at 300 mg BID.

Curis reported a net loss of $11.6 million, or $0.12 per share, for the first quarter of 2023. Revenues were $2.3 million, and the company's cash and investments totaled $71.8 million. The company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3.

Curis reported its Q4 2022 financial results, with a net loss of $11.3 million, or $0.12 per share. The company also announced the completion of enrollment for the additional patients requested by the FDA in the TakeAim Leukemia study.

Curis reported a net loss of $13.3 million for the third quarter of 2022, compared to a net loss of $11.1 million for the same period in 2021. The company is prioritizing the development of emavusertib and expects its cash runway to extend into 2025.

Curis reported a net loss of $15.9 million, or $0.17 per share, for the second quarter of 2022. The company's cash, cash equivalents, and investments totaled $107.2 million as of June 30, 2022, which is expected to fund operations into 2024. The company also presented encouraging clinical data for emavusertib in combination with ibrutinib.

Curis reported a net loss of $16.1 million, or $0.18 per share, for the first quarter of 2022. Revenues were $2.1 million, primarily from royalty revenues. The company's cash, cash equivalents, and investments totaled $120.7 million as of March 31, 2022, expected to fund operations into 2024. Two TakeAim studies were put on partial clinical hold by the FDA.

Curis reported a net loss of $13.6 million, or $0.15 per share, for the fourth quarter of 2021. The company's cash, cash equivalents and investments totaled $139.8 million as of December 31, 2021, and it expects to maintain planned operations into 2024.

Curis reported a net loss of $11.1 million, or $0.12 per share, for the third quarter of 2021, compared to a net loss of $6.0 million, or $0.11 per share, for the same period in 2020. Revenues for the third quarter of 2021 were $3.0 million, compared to $2.7 million for the same period in 2020. The company's cash, cash equivalents and investments totaled $149.8 million as of September 30, 2021.

Curis reported a net loss of $10.8 million, or $0.12 per share, for the second quarter of 2021. The company continued to advance its pipeline of cancer therapies, particularly CA-4948, and presented updated clinical data at the European Hematology Association (EHA) Virtual Congress.

Curis reported a net loss of $9.9 million, or $0.11 per share, for the first quarter of 2021, compared to a net loss of $9.7 million, or $0.28 per share, for the same period in 2020. Revenues for the first quarter of 2021 were $2.2 million, compared to $2.7 million for the same period in 2020. As of March 31, 2021, Curis's cash, cash equivalents and investments totaled $168.4 million.

Curis, Inc. reported a net loss of $7.5 million, or $0.11 per share, for Q4 2020. Revenues for the quarter were $3.0 million. The company's cash, cash equivalents, and investments totaled $183.1 million as of December 31, 2020, expected to fund operations into 2024.

Curis, Inc. reported a net loss of $6.0 million, or $0.11 per share, for the third quarter of 2020, compared to a net loss of $6.4 million, or $0.19 per share, for the same period in 2019. Revenues for the quarter were $2.7 million, primarily from royalty revenues on Genentech and Roche's sales of Erivedge.

Curis reported a net loss of $6.7 million, or $0.17 per share, for the second quarter of 2020, compared to a net loss of $7.2 million, or $0.22 per share, for the same period in 2019. Revenues for the second quarter of 2020 were $2.4 million, compared to $2.1 million for the same period in 2019. The company's cash, cash equivalents, marketable securities and investments totaled $23.6 million as of June 30, 2020.

Curis reported a net loss of $9.7 million, or $0.28 per share, for the first quarter of 2020. Revenues for the quarter were $2.7 million, primarily from royalty revenues on Genentech and Roche's Erivedge sales. The company's cash, cash equivalents, and investments totaled $12.5 million as of March 31, 2020.

Curis reported a net loss of $8.6 million for the fourth quarter of 2019, compared to a net loss of $5.9 million for the same period in 2018. Revenues for the fourth quarter of 2019 were $3.3 million, compared to $2.8 million for the same period in 2018. The company is prioritizing resources for CA-4948 and CI-8993 clinical development programs and discontinuing the fimepinostat-venetoclax combination study.